F. Yang

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.

I. Pavord, C. Brightling, R. Chaudhuri, 2021, The Lancet. Respiratory medicine.

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

I. Pavord, A. Woodcock, P. Howarth, 2020, The Lancet. Respiratory medicine.

Factors associated with frequent exacerbations in the UK Severe Asthma Registry.

N. Thomson, C. Brightling, R. Chaudhuri, 2021, The journal of allergy and clinical immunology. In practice.